metastatic melanoma

July 12, 2017

Gene Expression Analysis Helps Determine Sensitivity to Immunotherapies

Researchers at Johns Hopkins University have discovered that variations in gene expression levels can provide insight into mechanisms that allow tumors to respond to immunotherapies. The study, “Transcriptional Mechanisms ... Read more

October 20, 2016

Metastatic Melanoma Immunotherapy Combo Shows Promise in Phase 1b/2 Trial

News

The experimental immunotherapy SD-101 combined with the anti-PD-1 agent Keytruda (pembrolizumab) is safe and may be a promising approach for patients with metastatic melanoma, according to data from a Phase 1b/2 ... Read more

October 7, 2016

New and Updated Data from Studies of Opdivo and Yervoy Being Presented at ESMO Congress

News

Bristol-Myers Squibb is presenting new data from numerous studies of its cancer therapies Opdivo (nivolumab) and Yervoy (ipilimumab) at the European Society for Medical Oncology (ESMO) 2016 Congress, with a particular focus on combination ... Read more

June 21, 2016June 21, 2016

NHS Approves Immunotherapy Combination for Metastatic Melanoma

News

Metastatic melanoma patients in England and Wales will be the first in Europe to benefit from the combined immunotherapy regimen of nivolumab (Opdivo) and ipilimumab (Yervoy). The therapy was recently approved by the National Institute for Health and Care Excellence (NICE). ... Read more

May 13, 2016May 13, 2016

Bim Marker May Predict Malignancy’s Response to Immunotherapy

News

Mayo Clinic researchers have found that the protein marker Bim may predict reponse in patients treated with anti-PD-1 immunotherapy. According to a recent study, the team believes measuring the Bim ... Read more

June 24, 2015June 24, 2015

Caladrius Biosciences Announces First Patient Dosed in Phase 3 trial of CLBS20 for Metastatic Melanoma

News

Caladrius Biosciences, Inc. recently announced its Intus Phase 3 study dosed the first patient with stage III recurrent or stage IV metastatic melanoma . The study, taking place at the ... Read more

March 9, 2015March 9, 2015

FDA Approves Opdivo for Treatment of Patients with Metastatic Squamous NSCLC

News

The U. S. Food and Drug Administration (FDA) approved Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with a diagnosis of metastatic squamous non-small cell lung cancer (NSCLC) with ... Read more

December 2, 2014

Researchers Use Tumor Antigens For Personalized Vaccines

News

In a recent study published in Nature, entitled “Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens”, a team of researchers from the Washington University School of Medicine found that ... Read more

November 10, 2014November 10, 2014

OncoSec Will Present Clinical Data At Melanoma Bridge 2014

News

OncoSec Medical Inc. will present clinical results evaluating the company’s ImmunoPulse immunotherapy at Melanoma Bridge 2014. The event will be held in Naples, Italy, at the Royal Continental Hotel. The company ... Read more

October 14, 2014October 14, 2014

Study Optimizes Platform to Expand Tumor Infiltrating Lymphocytes (TILs) For Melanoma Treatment

News

In a recent study titled “Activation and Propagation of Tumor-infiltrating Lymphocytes on Clinical-grade Designer Artificial Antigen-presenting Cells for Adoptive Immunotherapy of Melanoma” published in the Journal of Immunotherapy, a ... Read more